Managed Healthcare Executive10h
Organon Expands Biosimilar Portfolio With Tofidence Acquisition
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
80 years after World War II, Okinawa’s battle sites are still giving up bones and bombs
An estimated 240,000 people were killed or went missing in the Battle of Okinawa during World War II. Eighty years later, the ...
Organon acquires rights for Tofidence from Biogen
Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...
eLife1d
Nora virus proliferates in dividing intestinal stem cells and sensitizes flies to intestinal infection and oxidative stress
This important study shows that the Nora virus, a natural Drosophila pathogen that also persistently infects many laboratory fly stocks, infects intestinal stem cells (ISCs), leading to a shorter life ...
Nexus Pharmaceuticals Launches Fluorescein 2 mL
Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL ...
DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...